Japan sales expected to exceed 2025 despite Q2 decline
Guidance tone
Aflac's Q2 2026 call revealed a solid quarter with adjusted EPS of $1.75, but the overall tone was neutral. The main strategic headlines were a significant $4.8 billion portfolio repositioning to boost investment income and a substantial expansion of the internal reinsurance target for Japan, signaling a more active capital management strategy. Guidance for US premium growth was slightly lowered. Adjusted EPS of $1.75 in Q2, up 1.1% year-over-year, with ROE at 12.7% (16.6% ex-FX).
Aflac's Q2 2026 call revealed a solid quarter with adjusted EPS of $1.75, but the overall tone was neutral. The main strategic headlines were a significant $4.8 billion portfolio repositioning to boost investment income and a substantial expansion of the internal reinsurance target for Japan, signaling a more active capital management strategy. Guidance for US premium growth was slightly lowered. Adjusted EPS of $1.75 in Q2, up 1.1% year-over-year, with ROE at 12.7% (16.6% ex-FX).
Guidance tone
Management highlighted strong sales momentum in Japan, particularly for the new Sumitas and Anshin Pallet products, and expects full-year Japan sales to exceed 2025. In the U.S., sales increased 2.6% year-over-year with particular strength in group voluntary and dental/vision…
Japan sales declined -5.6% in the quarter but remain up 7% for the first half; management still expects full-year sales to exceed 2025.
Aflac repositioned $4.8 billion in investments via switch trades, expecting to boost net investment income by over $50 million annually.
Management highlighted strong sales momentum in Japan, particularly for the new Sumitas and Anshin Pallet products, and expects full-year Japan sales to exceed 2025. In the U.S., sales increased 2.6% year-over-year with particular strength in group voluntary and dental/vision products, and management expects a stronger second half with growth higher than last year.
Management expressed confidence in the business and strategic initiatives, but also acknowledged headwinds such as elevated benefit ratios and a competitive sales environment.
“During the quarter, our global investments team were quite active repositioning $4.8 billion of their portfolio through switch trades to capture the benefit of higher yields and further strengthen the overall quality of our consolidated po…”
“We have revisited this target and aligned it with an FSA perspective of up to 30% of FSA reserves. This will allow us to continue to reduce risk, improve balance sheet efficiency, and ultimately generate a higher ROE for Affleck Japan and…”
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| Op margin | FY2026 | 60%–63%inline 컨센서스 대비 | 61.5% | MAINTAINED |
| Op margin | FY2026 | 3%–6%inline 컨센서스 대비 | 4.5% | LOWERED |